FDA Brief

Warning letters Drugs

FDA warning letter to

LightEyez Limited

High riskIssued Feb 15, 2024Posted Feb 27, 2024Center for Drug Evaluation and Research | CDER

LightEyez eye drops sold in the U.S. were contaminated with microbes, and FDA cited unapproved new drug claims for its eye drops.

What happened

FDA bought MSM Eye Repair Drops batch "P15D7 April 11th 2023" directly from the LightEyez website and laboratory testing found gross microbial growth in all ten composite samples, including Pseudomonas and Mycobacterium. FDA also reviewed the firm's website and labeling in August and September 2023 and found claims that make its MSM, color changing and eye lightening eye drops unapproved new drugs. When FDA tried an on-site investigation at the U.S. manufacturer's address on September 15, 2023, neither the manufacturer nor LightEyez was found there, and the firm stopped communicating with FDA.

What FDA found

  1. All ten samples of the eye drop batch FDA tested had gross microbial contamination, including Pseudomonas and Mycobacterium.

    FD&C Act section 501(a)(1), 21 U.S.C. 351(a)(1)
  2. The company did not follow CGMP (required manufacturing quality rules for drugs) and did not adequately oversee its manufacturer, including the manufacturer's use of unfiltered municipal water.

    21 CFR 211.22(a); 21 CFR Parts 210 and 211
  3. The eye drop products are unapproved new drugs sold without an FDA-approved application.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  4. The website tells consumers to push a foreign object into the dropper tip or remove the tip to clear blockages, and says containers leak, which risks contaminating the eye drops.

  5. The firm agreed to recall all its sterile drug products in U.S. distribution but has not initiated a recall through FDA, posting a notice covering only one batch.

What FDA wants

Respond in writing within 15 working days describing what you have done to correct the violations and prevent recurrence. FDA also asks for the updated headquarters address, all facilities and contract manufacturers making your U.S. drug products, a complete list of your drug products sold in the U.S., complete contamination investigations, and a recall of all batches of MSM Eye Repair Drops and other sterile products.

Who should pay attention

  • brands that buy eye drops or drug components from contract manufacturers
  • retailers and online marketplaces listing imported eye drop products
  • ingredient suppliers shipping drug components to U.S. manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk